← 返回

TIL(肿瘤浸润淋巴细胞)的活化向记忆分化轨迹揭示转移性黑色素瘤的预后

英文原题:An activation to memory differentiation trajectory of tumor-infiltrating lymphocytes informs metastatic melanoma outcomes.

查看英文原题

An activation to memory differentiation trajectory of tumor-infiltrating lymphocytes informs metastatic melanoma outcomes.

PubMed 2022/05/09(内容时间) Cancer Cell Q1 · IF 56.1(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

需要对TIL(肿瘤浸润淋巴细胞)(TILs)进行更好的分类和理解。在此,我们应用先进的功能基因组学,使用基准化的T细胞状态、全面的T细胞分化轨迹、人类和小鼠疫苗应答以及其他人类TILs,对9,000例人类肿瘤和多个单细胞测序数据集进行了探究。与其他T细胞状态相比,在实体瘤中观察到T记忆/组织驻留记忆程序的富集。对单细胞黑色素瘤CD8+ TILs的轨迹分析还发现,在抗PD-1应答者中存在高比例的记忆/组织驻留记忆评分TILs,且这些TILs在治疗后扩增。相反,早期T细胞活化评分高但耗竭评分不高的TILs与无应答相关。晚期/持续性活化特征而非早期活化特征可预测黑色素瘤生存,并与树突状细胞和IFN-γ应答程序共表达。这些数据鉴定出一种与不良应答相关的活化样状态,并提示成功的记忆转化——而非耗竭的复苏——是成功抗肿瘤免疫中一个未被充分认识的重要方面。

展开英文摘要原文

There is a need for better classification and understanding of tumor-infiltrating lymphocytes (TILs).

Here, we applied advanced functional genomics to interrogate 9,000 human tumors and multiple single-cell sequencing sets using benchmarked T cell states, comprehensive T cell differentiation trajectories, human and mouse vaccine responses, and other human TILs. Compared with other T cell states, enrichment of T memory/resident memory programs was observed across solid tumors. Trajectory analysis of single-cell melanoma CD8 + TILs also identified a high fraction of memory/resident memory-scoring TILs in anti-PD-1 responders, which expanded post therapy.

In contrast, TILs scoring highly for early T cell activation, but not exhaustion, associated with non-response. Late/persistent, but not early activation signatures, prognosticate melanoma survival, and co-express with dendritic cell and IFN-γ response programs. These data identify an activation-like state associated to poor response and suggest successful memory conversion, above resuscitation of exhaustion, is an under-appreciated aspect of successful anti-tumoral immunity.

论文信息

作者
Jaiswal A、Verma A、Dannenfelser R、Melssen M、Tirosh I、Izar B、Kim TG、Nirschl CJ
第一作者单位
Department of Dermatology, Weill Cornell Medicine, New York, NY 10026, USA; Immunology and Microbial Pathogenesis Program, Weill Cornell Medicine, New York, NY 10026, USA.United States
通讯作者单位
Department of Dermatology, Weill Cornell Medicine, New York, NY 10026, USA; Immunology and Microbial Pathogenesis Program, Weill Cornell Medicine, New York, NY 10026, USA; Institute for Computational Biomedicine, Caryl and Israel Englander Institute for Precision Medicine, Weill Cornell Medicine, New York, NY, USA; Sandra and Edward Meyer Cancer Center, Weill Cornell Medicine, New York, NY 10026, USA; Department of Microbiology and Immunology, Weill Cornell Medicine, New York, NY 10026, USA. Electronic address: nia9069@med.cornell.edu.United States
文献类型
非美国政府资助研究 · 美国 NIH 资助研究
期刊
Cancer cell2022 May 9
原文标识
PubMed 35537413 · DOI 10.1016/j.ccell.2022.04.005